DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 interim analysis in H1 2026 as enrollment momentum builds
Source: SeekingAlpha
2025-05-14 11:06:10 ET
More on DiaMedica Therapeutics
- DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript
- DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve
- DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript
- DiaMedica Therapeutics GAAP EPS of -$0.18 in-line
- DiaMedica Therapeutics GAAP EPS of -$0.60 misses by $0.01
Read the full article on Seeking Alpha
For further details see:
DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 interim analysis in H1 2026 as enrollment momentum builds
DiaMedica Therapeutics Inc.
NASDAQ: DMAC
DMAC Trading
-5.35% G/L:
$7.07 Last:
92,570 Volume:
$7.32 Open:
DMAC Latest News
March 05, 2026 07:35:00 am
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
February 24, 2026 09:23:00 am
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
January 16, 2026 05:00:00 pm
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 18, 2025 08:45:00 am
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
DMAC Stock Data
$439,533,585
29,684,140
16.95%
29
N/A
Biotechnology & Life Sciences
Healthcare
US
Minneapolis
